Bharat Biotech is in the process of filing regulatory documents for approval of its COVID-19 vaccine, Covaxin in more than 40 countries, the company told Reuters on Wednesday.
“We have submitted our documentation in Brazil and other countries and await their approval. We plan to export several million doses to Brazil,” the company said in an emailed statement. “Pricing of Covaxin for international markets will be based upon supply timelines, purchase commitments and procurement volumes,” it added.
Meanwhile, Bharat Biotech has also entered into an agreement with US-based Ocugen to supply its COVID-19 vaccine in the US market. The company, however, has not named other countries where it expects to export the Covaxin doses. Also Read: Bharat Biotech signs agreement with Ocugen to supply Covaxin in US
Covaxin and Covishield are the two vaccines approved for emergency use in India. While Covishield is originally the Oxford-AstraZeneca vaccine manufactured by the Serum Institute of India, Covaxin is Bharat Biotech’s homegrown vaccine. The efficacy data from Covaxin’s late-stage trial is yet to come and the company expects results from an ongoing trial involving 25,800 participants in India by March. Also Read: India vaccinates 80 lakh beneficiaries against COVID-19 in 28 days